Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours

A. Boiardi, M. Eoli, A. Salmaggi, B. Zappacosta, L. Fariselli, I. Milanesi, G. Broggi, A. Silvani

Research output: Contribution to journalArticle

Abstract

Ninety-nine patients bearing recurrent malignant glioma sequentially selected according to strict eligibility criteria (72 GBL and 27 AA) entered the study. All patients were previously managed with radiotherapy 60 Gy total dose and chemotherapy with nitrosoureas and platinum compounds. At recurrence they were subdivided in homogeneous groups, all treated with the same systemic chemotherapy protocol: 27 GBL (group A) only systemically treated, 20 GBL (group B) treated also locally by delivering 4 mg of mitoxantrone every 20 days through the Ommaya reservoire, and 25 GBL (group C) treated with a second surgery and locally as group B. Of the AA group, 13/27 were treated locally through the Ommaya reservoir after repeat surgery. A trend to different demographic features among subgroups (with locoregionally treated patients and patients undergoing repeat surgery being younger than the others) was seen in this non-randomized study, but this was not statistically significant. Median overall survival was 27, 26 and 15.5 months respectively for groups c, b and a (log-rank = 0.1). After tumor recurrence median survival was 16.8, 12 and 6.6 months respectively for groups c, b and a (log-rank = 0.001). For the 29 AA, overall survival was 48.5 and 100 months (log-rank = 0.03) if treated locally with second tumor debulking. Our results stress the opinion that a second operation could be indicated only if it is a part of a therapeutic protocol to allow a locoregional treatment. Moreover we can finally assume that local delivery of chemotherapy after tumor recurrence, possibly extends patients survival but certainly improves the number of long-survivors.

Original languageEnglish
Pages (from-to)39-47
Number of pages9
JournalJournal of Neuro-Oncology
Volume54
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

Mitoxantrone
Neuroglia
Survival
Neoplasms
Reoperation
Recurrence
Drug Therapy
Nitrosourea Compounds
Platinum Compounds
Glioma
Survivors
Radiotherapy
Referral and Consultation
Demography
Therapeutics

Keywords

  • Locoregional therapy
  • Mitoxantrone
  • Recurrent malignant glial tumours

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. / Boiardi, A.; Eoli, M.; Salmaggi, A.; Zappacosta, B.; Fariselli, L.; Milanesi, I.; Broggi, G.; Silvani, A.

In: Journal of Neuro-Oncology, Vol. 54, No. 1, 2001, p. 39-47.

Research output: Contribution to journalArticle

Boiardi, A. ; Eoli, M. ; Salmaggi, A. ; Zappacosta, B. ; Fariselli, L. ; Milanesi, I. ; Broggi, G. ; Silvani, A. / Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. In: Journal of Neuro-Oncology. 2001 ; Vol. 54, No. 1. pp. 39-47.
@article{10d215488771494496ac20e7a4c41ac4,
title = "Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours",
abstract = "Ninety-nine patients bearing recurrent malignant glioma sequentially selected according to strict eligibility criteria (72 GBL and 27 AA) entered the study. All patients were previously managed with radiotherapy 60 Gy total dose and chemotherapy with nitrosoureas and platinum compounds. At recurrence they were subdivided in homogeneous groups, all treated with the same systemic chemotherapy protocol: 27 GBL (group A) only systemically treated, 20 GBL (group B) treated also locally by delivering 4 mg of mitoxantrone every 20 days through the Ommaya reservoire, and 25 GBL (group C) treated with a second surgery and locally as group B. Of the AA group, 13/27 were treated locally through the Ommaya reservoir after repeat surgery. A trend to different demographic features among subgroups (with locoregionally treated patients and patients undergoing repeat surgery being younger than the others) was seen in this non-randomized study, but this was not statistically significant. Median overall survival was 27, 26 and 15.5 months respectively for groups c, b and a (log-rank = 0.1). After tumor recurrence median survival was 16.8, 12 and 6.6 months respectively for groups c, b and a (log-rank = 0.001). For the 29 AA, overall survival was 48.5 and 100 months (log-rank = 0.03) if treated locally with second tumor debulking. Our results stress the opinion that a second operation could be indicated only if it is a part of a therapeutic protocol to allow a locoregional treatment. Moreover we can finally assume that local delivery of chemotherapy after tumor recurrence, possibly extends patients survival but certainly improves the number of long-survivors.",
keywords = "Locoregional therapy, Mitoxantrone, Recurrent malignant glial tumours",
author = "A. Boiardi and M. Eoli and A. Salmaggi and B. Zappacosta and L. Fariselli and I. Milanesi and G. Broggi and A. Silvani",
year = "2001",
doi = "10.1023/A:1012510513780",
language = "English",
volume = "54",
pages = "39--47",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours

AU - Boiardi, A.

AU - Eoli, M.

AU - Salmaggi, A.

AU - Zappacosta, B.

AU - Fariselli, L.

AU - Milanesi, I.

AU - Broggi, G.

AU - Silvani, A.

PY - 2001

Y1 - 2001

N2 - Ninety-nine patients bearing recurrent malignant glioma sequentially selected according to strict eligibility criteria (72 GBL and 27 AA) entered the study. All patients were previously managed with radiotherapy 60 Gy total dose and chemotherapy with nitrosoureas and platinum compounds. At recurrence they were subdivided in homogeneous groups, all treated with the same systemic chemotherapy protocol: 27 GBL (group A) only systemically treated, 20 GBL (group B) treated also locally by delivering 4 mg of mitoxantrone every 20 days through the Ommaya reservoire, and 25 GBL (group C) treated with a second surgery and locally as group B. Of the AA group, 13/27 were treated locally through the Ommaya reservoir after repeat surgery. A trend to different demographic features among subgroups (with locoregionally treated patients and patients undergoing repeat surgery being younger than the others) was seen in this non-randomized study, but this was not statistically significant. Median overall survival was 27, 26 and 15.5 months respectively for groups c, b and a (log-rank = 0.1). After tumor recurrence median survival was 16.8, 12 and 6.6 months respectively for groups c, b and a (log-rank = 0.001). For the 29 AA, overall survival was 48.5 and 100 months (log-rank = 0.03) if treated locally with second tumor debulking. Our results stress the opinion that a second operation could be indicated only if it is a part of a therapeutic protocol to allow a locoregional treatment. Moreover we can finally assume that local delivery of chemotherapy after tumor recurrence, possibly extends patients survival but certainly improves the number of long-survivors.

AB - Ninety-nine patients bearing recurrent malignant glioma sequentially selected according to strict eligibility criteria (72 GBL and 27 AA) entered the study. All patients were previously managed with radiotherapy 60 Gy total dose and chemotherapy with nitrosoureas and platinum compounds. At recurrence they were subdivided in homogeneous groups, all treated with the same systemic chemotherapy protocol: 27 GBL (group A) only systemically treated, 20 GBL (group B) treated also locally by delivering 4 mg of mitoxantrone every 20 days through the Ommaya reservoire, and 25 GBL (group C) treated with a second surgery and locally as group B. Of the AA group, 13/27 were treated locally through the Ommaya reservoir after repeat surgery. A trend to different demographic features among subgroups (with locoregionally treated patients and patients undergoing repeat surgery being younger than the others) was seen in this non-randomized study, but this was not statistically significant. Median overall survival was 27, 26 and 15.5 months respectively for groups c, b and a (log-rank = 0.1). After tumor recurrence median survival was 16.8, 12 and 6.6 months respectively for groups c, b and a (log-rank = 0.001). For the 29 AA, overall survival was 48.5 and 100 months (log-rank = 0.03) if treated locally with second tumor debulking. Our results stress the opinion that a second operation could be indicated only if it is a part of a therapeutic protocol to allow a locoregional treatment. Moreover we can finally assume that local delivery of chemotherapy after tumor recurrence, possibly extends patients survival but certainly improves the number of long-survivors.

KW - Locoregional therapy

KW - Mitoxantrone

KW - Recurrent malignant glial tumours

UR - http://www.scopus.com/inward/record.url?scp=0035182616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035182616&partnerID=8YFLogxK

U2 - 10.1023/A:1012510513780

DO - 10.1023/A:1012510513780

M3 - Article

C2 - 11763421

AN - SCOPUS:0035182616

VL - 54

SP - 39

EP - 47

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -